New drug SYNT-101 tested for safety in first human study
NCT ID NCT07307274
First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 24 times
Summary
This early-phase study tests the safety and tolerability of a new drug called SYNT-101 in healthy adults and those who are overweight or have obesity. About 64 participants will receive either the drug or a placebo to monitor side effects and how the drug moves through the body. The goal is not to treat a condition but to gather essential safety data before further research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Veritus Research
RECRUITINGBayswater, Victoria, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.